title: Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells.
abstract: Angiogenesis induced by proangiogenic molecules such as vascular endothelial growth factor (VEGF) is a key process in the progression and metastasis of gastric cancer. In this study, we investigated the role of VEGF-C/VEGF receptor 3 (VEGFR3) axis in cell proliferation and migration/invasion of human gastric cancer cells (hGCCs). VEGF-C did not enhance cell proliferation but increased cell migration/invasion by approximately ∼50% in hGCCs (AGS and SNU-484). MAZ51, a VEGFR3 inhibitor, reduced the VEGF-C-induced increase in migration/invasion by ∼30% (p < 0.05). These results suggest that VEGFR3 could be a therapeutic target for reducing the metastasis of gastric cancer cells.
authors.affiliation: a Department of Pediatrics, Institute of Health Sciences , Gyeongsang National University School of Medicine , Jinju , South Korea.
authors.forename: Jaeyoung
authors.initials: J
authors.lastname: Lim
authors.affiliation: b Department of Physiology, Institute of Health Sciences , Gyeongsang National University School of Medicine , Jinju , South Korea.
authors.forename: Ji Hyeon
authors.initials: JH
authors.lastname: Ryu
authors.affiliation: b Department of Physiology, Institute of Health Sciences , Gyeongsang National University School of Medicine , Jinju , South Korea.
authors.forename: Eun-Jin
authors.initials: EJ
authors.lastname: Kim
authors.affiliation: b Department of Physiology, Institute of Health Sciences , Gyeongsang National University School of Medicine , Jinju , South Korea.
authors.forename: Songhee
authors.initials: S
authors.lastname: Ham
authors.affiliation: b Department of Physiology, Institute of Health Sciences , Gyeongsang National University School of Medicine , Jinju , South Korea.
authors.forename: Dawon
authors.initials: D
authors.lastname: Kang
mesh_terms: D045744:Cell Line, Tumor / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D058990:Molecular Targeted Therapy / Q000379:methods; D009281:Naphthalenes / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism / Q000494:pharmacology; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: C441602:3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one; D007211:Indoles; D009281:Naphthalenes; D047428:Protein Kinase Inhibitors; D042582:Vascular Endothelial Growth Factor C; C581309:FLT4 protein, human; D040321:Vascular Endothelial Growth Factor Receptor-3
keywords: Cell movement; Gastric neoplasms; Vascular endothelial growth factor C; Vascular endothelial growth factor receptor-3